Virological safety aspects of plasma derivatives : cannes(France) November 3-6, 1992
著者
書誌事項
Virological safety aspects of plasma derivatives : cannes(France) November 3-6, 1992
(Developments in biological standardization, v. 81)
Karger, c1993
大学図書館所蔵 全2件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Proceedings of a Symposium organized by the International Association of Biological Standardization and co-sponsored by the World Health Organization, the Council of Europe, European Pharmacopoeia, the International Society of Blood Transfusion and the Department of Health & Human Services F.D.A.(USA)
内容説明・目次
内容説明
Human plasma pools used for the preparation of therapeutic products are known to carry a certain risk of transmitting viruses which cause diseases such as AIDS and hepatitis B and C. This volume brings the reader up to date with the efforts being made at all levels to ensure the safety of plasma-derived products. Emphasis is placed on the factors most important for product safety, such as donor selection, testing of individual units, control of the manufacturing process, the use of inactivation and/or elimination procedures, and end-product testing for infectious agents. Regulatory activities and the role of the WHO are also discussed. With contributions from leading experts, this volume is a valuable resource for all those concerned with the virological safety of plasma derivatives.
目次
- Opening conference - hepatitis overview - viral hepatitis - one disease but multiple viruses, J.L. Melnick
- session I - virology and epidemiology, chairman - F. Horaud
- session II - selection of source material, chairman - J.W. Mosley
- session III - testing for viral markers, chairman - J. Finlayson
- session IV - general considerations on viral inactivation and/or elimination, chairman - I. Gust
- session V - critical views on methods used for viral inactivation and/or elimination, chairman - W.G. van Aken
- session VI - validation of viral inactivation and/or elimination, chairman - G. Schild
- session VII - regulatory aspects of safety, chairman - I. Sjoholm
- session VIII - summary and conclusion, chairman - G. Vicari.
「Nielsen BookData」 より